Media Coverage
October 2025 – Let’s Win Pancreatic Cancer
Early nine-month data from a clinical trial suggests a new promising first-line treatment option for patients newly diagnosed with pancreatic cancer. Read More »
October 2025 – Targeted Oncology
Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments. Read More »
September 2025 – OncLive
First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer Read More »
September 2025 – Endpoints News
Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year Read More »
July 2025 – PharmaVoice
The MEK effect on cancer — a slow and steady approach to drug resistance Read More »
June 2025 – Targeted Oncology
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer Read More »
June 2025 – OncLive
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer Read More »
June 2025 – Fierce Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans Read More »
June 2025 – Cancer Network
Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC Read More »
June 2025 – FirstWord Pharma
Immuneering touts strong survival in pancreatic cancer trial Read More »
June 2025 – Endpoints News
Immuneering says MEK pill beats standard of care in first-line pancreatic cancer Read More »
Page 1 of 1
